Glenmark’s Research & Development is committed to identifying products that fulfill unique and unmet medical needs in inflammatory disorders, especially in respiratory and dermatology therapies. In, addition oncology is also a key focus area.

With more than 350 scientists dedicated to new chemical entity (NCE) research and more than 100 scientists involved in new biologic entity (NBE) research, we have developed an enviable and robust pipeline anchored in first- and best-in-class discovery. With 4 NBEs, 3 NCEs and a biosimilar candidate in various stages of clinical development, Glenmark is delivering on its commitment to bring the best science to patients worldwide.